Nanoparticles for sustained release of active agents for the treatment of pulmonary hypertension
Pulmonary hypertension is a serious, lifethreatening
disorder which substantially restricts physical capacities and results in a severely reduced life expectancy with an average survival time of only 2.8 years after diagnosis if the disease is not treated.<br> The new nanoparticles now allow a controlled release of inhalable active agents for pulmonary hypertension over a long period of time, thus leading to a prolongation of pharmacological effects and a considerably improved quality of patients' life.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Superradiant atoms could push the boundaries of how precisely time can be measured
Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…
Ion thermoelectric conversion devices for near room temperature
The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…